+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07522073

Randomized Study of Chemotherapy With or Without INCB161734 in Untreated KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Led by Incyte Corporation · Updated on 2026-10-30

588

Participants Needed

230

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.

CONDITIONS

Brief Title

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Research Team

I

Incyte Corporation Call Center (US)

I

Incyte Corporation Call Center (ex-US)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here